RSS-Feed abonnieren
DOI: 10.1055/s-0034-1375962
Drug-Induced Liver Injury and Drug Development: Industry Perspective
Publikationsverlauf
Publikationsdatum:
31. Mai 2014 (online)
![](https://www.thieme-connect.de/media/sld/201402/lookinside/thumbnails/10.1055-s-0034-1375962-1.jpg)
Abstract
Despite intensive ongoing research, drug-induced live injury (DILI) remains a serious issue for care providers and patients, and has been a major cause of drug withdrawal and non-approval by regulatory authorities in the past 50 years. Consequently, DILI remains a major concern for the pharmaceutical industry and a leading cause for attrition during drug development. In most instances, severe DILI is an uncommon idiosyncratic reaction, which typically does not present during preclinical phases or early clinical phases of drug development. In the majority of cases, drugs that caused severe DILI in humans have not shown clear and consistent hepatotoxic signals in preclinical assessment including animal studies, cell cultures, or other methods. Despite intensive efforts to develop better biomarkers that would help in predicting DILI risk in earlier phases of drug development, such biomarkers are currently not supported by sufficient evidence and are not yet available for routine use by drug makers. Due to the lack of effective and accurate methods for prediction of idiosyncratic DILI during preclinical phases of drug development, different drug makers have adopted different approaches, which are often not supported by strong systematic evidence. Based on growing experience, it is becoming increasingly evident that milder forms of liver injury occurring during clinical development, when assessed correctly, may significantly enhance our ability to predict the drug's potential to cause more severe liver injury postmarketing. Strategies based on this concept have been adopted by many drug makers, and are being increasingly implemented during drug development. Meticulous causality assessment of individual hepatic cases and adherence to strict hepatic discontinuation rules are critical components of this approach and have to rely on thorough clinical evaluation and occasionally on assessment by liver experts experienced with DILI and drug development.
-
References
- 1 Stevens JL, Baker TK. The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov Today 2009; 14 (3-4) 162-167
- 2 Watkins PB, Seligman PJ, Pears JS, Avigan MI, Senior JR. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology 2008; 48 (5) 1680-1689
- 3 FDA. Guidance for industry. Drug-induced livery injury: premarketing clinical evaluation. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf . Accessed December 17, 2013
- 4 Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354 (7) 731-739
- 5 Goodman ZD. Drug hepatotoxicity. Clin Liver Dis 2002; 6 (2) 381-397
- 6 Lewis JH, Ahmed M, Shobassy A, Palese C. Drug-induced liver disease. Curr Opin Gastroenterol 2006; 22 (3) 223-233
- 7 Bhamidimarri KR, Schiff E. Drug-induced cholestasis. Clin Liver Dis 2013; 17 (4) 519-531 , vii
- 8 Patel V, Sanyal AJ. Drug-induced steatohepatitis. Clin Liver Dis 2013; 17 (4) 533-546 , vii
- 9 Lewis JH. Drug-induced liver injury throughout the drug development life cycle: where we have been, where we are now, and where we are headed. Perspectives of a clinical hepatologist. Pharm Med 2013; 27: 165-191
- 10 Zimmerman HJ. Drug-induced liver disease. In: Hepatotoxicity, The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1999: 428-433
- 11 Zetzel L, Kaplan H. Liver damage concurrent with iproniazid administration. N Engl J Med 1958; 258 (24) 1209-1211
- 12 Zimmerman HJ, Rosenblum L, Korn RJ, Feldman PE. Some preliminary clinical and biochemical aspects of liver function in patients receiving iproniazid. Ann N Y Acad Sci 1959; 80: 915-927
- 13 Manier JW, Chang WW, Kirchner JP, Beltaos E. Hepatotoxicity associated with ticrynafen—a uricosuric diuretic. Am J Gastroenterol 1982; 77 (6) 401-404
- 14 Zimmerman HJ, Lewis JH, Ishak KG, Maddrey WC. Ticrynafen-associated hepatic injury: analysis of 340 cases. Hepatology 1984; 4 (2) 315-323
- 15 NIDDK. LiverTox, Clinical and research information on drug-induced liver injury. Available at: http://livertox.nlm.nih.gov/Isoniazid.htm . Accessed January 7, 2014
- 16 Walker RM, McElligott TF. Furosemide induced hepatotoxicity. J Pathol 1981; 135 (4) 301-314
- 17 Taggart HM, Alderdice JM. Fatal cholestatic jaundice in elderly patients taking benoxaprofen. Br Med J (Clin Res Ed) 1982; 284 (6326) 1372
- 18 Hamdy RC, Murnane B, Perera N, Woodcock K, Koch IM. The pharmacokinetics of benoxaprofen in elderly subjects. Eur J Rheumatol Inflamm 1982; 5 (2) 69-75
- 19 Moses PL, Schroeder B, Alkhatib O, Ferrentino N, Suppan T, Lidofsky SD. Severe hepatotoxicity associated with bromfenac sodium. Am J Gastroenterol 1999; 94 (5) 1393-1396
- 20 Hunter EB, Johnston PE, Tanner G, Pinson CW, Awad JA. Bromfenac (Duract)-associated hepatic failure requiring liver transplantation. Am J Gastroenterol 1999; 94 (8) 2299-2301
- 21 Rabkin JM, Smith MJ, Orloff SL, Corless CL, Stenzel P, Olyaei AJ. Fatal fulminant hepatitis associated with bromfenac use. Ann Pharmacother 1999; 33 (9) 945-947
- 22 Fontana RJ, McCashland TM, Benner KG , et al; The Acute Liver Failure Study Group. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. Liver Transpl Surg 1999; 5 (6) 480-484
- 23 Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998; 129 (1) 36-38
- 24 Vella A, de Groen PC, Dinneen SF. Fatal hepatotoxicity associated with troglitazone. Ann Intern Med 1998; 129 (12) 1080
- 25 Herrine SK, Choudhary C. Severe hepatotoxicity associated with troglitazone. Ann Intern Med 1999; 130 (2) 163-164
- 26 Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338 (13) 916-917
- 27 Maria VA, Victorino RM. Hypersensitivity immune reaction as a mechanism for dilevalol-associated hepatitis. Ann Pharmacother 1992; 26 (7-8) 924-926
- 28 He R. 2004, Clinical Review of Exanta (ximelagatran) Tablets, FDA Cardiovascular and Renal Drugs Advisory Committee Briefing Information. Available at: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4069B1_01_AstraZeneca-Backgrounder.pdf . Accessed January 7, 2014
- 29 Lee WM, Larrey D, Olsson R , et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 2005; 28 (4) 351-370
- 30 Ainscow EK, Pilling JE, Brown NM , et al. Investigations into the liver effects of ximelagatran using high content screening of primary human hepatocyte cultures. Expert Opin Drug Saf 2008; 7 (4) 351-365
- 31 Kenne K, Skanberg I, Glinghammar B , et al. Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran. Toxicol In Vitro 2008; 22 (3) 730-746
- 32 Kramer JA, Sagartz JE, Morris DL. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat Rev Drug Discov 2007; 6 (8) 636-649
- 33 Olson H, Betton G, Robinson D , et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000; 32 (1) 56-67
- 34 Release of Guidance Document Pre-market evaluation of hepatotoxicity in health Products. Available at: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/prodpharma/applic-demande/guide-ld/hepatotox_guide_ld-eng.pdf Accessed January 10, 2014
- 35 Uetrecht J. Idiosyncratic drug reactions: past, present, and future. Chem Res Toxicol 2008; 21 (1) 84-92
- 36 Horsmans Y, Desager JP, Harvengt C. Biochemical changes and morphological alterations of the liver in guinea-pigs after administration of simvastatin (HMG CoA reductase-inhibitor). Pharmacol Toxicol 1990; 67 (4) 336-339
- 37 Kornbrust DJ, MacDonald JS, Peter CP , et al. Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits. J Pharmacol Exp Ther 1989; 248 (2) 498-505
- 38 Roth RA, Ganey PE. Animal models of idiosyncratic drug-induced liver injury—current status. Crit Rev Toxicol 2011; 41 (9) 723-739
- 39 Corsini A, Ganey P, Ju C , et al. Current challenges and controversies in drug-induced liver injury. Drug Saf 2012; 35 (12) 1099-1117
- 40 Katoh M, Matsui T, Nakajima M , et al. Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab Dispos 2004; 32 (12) 1402-1410
- 41 Antoine DJ, Williams DP, Park BK. Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science. Expert Opin Drug Metab Toxicol 2008; 4 (11) 1415-1427
- 42 Kalgutkar AS, Gardner I, Obach RS , et al. A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab 2005; 6 (3) 161-225
- 43 Williams DP. Toxicophores: investigations in drug safety. Toxicology 2006; 226 (1) 1-11
- 44 Iwanaga T, Nakakariya M, Yabuuchi H, Maeda T, Tamai I. Involvement of bile salt export pump in flutamide-induced cholestatic hepatitis. Biol Pharm Bull 2007; 30 (4) 739-744
- 45 Usui T, Mise M, Hashizume T, Yabuki M, Komuro S. Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Drug Metab Dispos 2009; 37 (12) 2383-2392
- 46 Obach RS, Kalgutkar AS, Soglia JR, Zhao SX. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem Res Toxicol 2008; 21 (9) 1814-1822
- 47 Park BK, Boobis A, Clarke S , et al. Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov 2011; 10 (4) 292-306
- 48 Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271 (13) 992-998
- 49 Liu ZX, Govindarajan S, Kaplowitz N. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology 2004; 127 (6) 1760-1774
- 50 Liu ZX, Han D, Gunawan B, Kaplowitz N. Neutrophil depletion protects against murine acetaminophen hepatotoxicity. Hepatology 2006; 43 (6) 1220-1230
- 51 Persson M, Løye AF, Mow T, Hornberg JJ. A high content screening assay to predict human drug-induced liver injury during drug discovery. J Pharmacol Toxicol Methods 2013; 68 (3) 302-313
- 52 Przybylak KR, Cronin MT. In silico models for drug-induced liver injury—current status. Expert Opin Drug Metab Toxicol 2012; 8 (2) 201-217
- 53 Zhang M, Chen M, Tong W. Is toxicogenomics a more reliable and sensitive biomarker than conventional indicators from rats to predict drug-induced liver injury in humans?. Chem Res Toxicol 2012; 25 (1) 122-129
- 54 Low Y, Uehara T, Minowa Y , et al. Predicting drug-induced hepatotoxicity using QSAR and toxicogenomics approaches. Chem Res Toxicol 2011; 24 (8) 1251-1262
- 55 Corvi R, Ahr HJ, Albertini S , et al. Meeting report: Validation of toxicogenomics-based test systems: ECVAM-ICCVAM/NICEATM considerations for regulatory use. Environ Health Perspect 2006; 114 (3) 420-429
- 56 Senior John . Lessons from isoniazid. Would it be approved today? Available at: www.fda.gov/downloads/Drugs/ScienceResearch/.../ucm076755.pdf . Accessed January 7, 2014
- 57 Mitchell JR, Long MW, Thorgeirsson UP, Jollow DJ. Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy. Chest 1975; 68 (2) 181-190
- 58 Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999; 281 (11) 1014-1018
- 59 Harrill AH, Roach J, Fier I , et al. The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers. Clin Pharmacol Ther 2012; 92 (2) 214-220
- 60 Cohen DE, Anania FA, Chalasani N ; National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol 2006; 97 (8A) 77C-81C
- 61 Olsson R, Korsan-Bengtsen BM, Korsan-Bengtsen K, Lennartsson J, Waldenström J. Serum aminotransferases after low-dose heparin treatment. Short communication. Acta Med Scand 1978; 204 (3) 229-230
- 62 Dukes Jr GE, Sanders SW, Russo Jr J , et al. Transaminase elevations in patients receiving bovine or porcine heparin. Ann Intern Med 1984; 100 (5) 646-650
- 63 Carlson MK, Gleason PP, Sen S. Elevation of hepatic transaminases after enoxaparin use: case report and review of unfractionated and low-molecular-weight heparin-induced hepatotoxicity. Pharmacotherapy 2001; 21 (1) 108-113
- 64 Lucena MI, Molokhia M, Shen Y , et al; Spanish DILI Registry; EUDRAGENE; DILIN; DILIGEN; International SAEC. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011; 141 (1) 338-347
- 65 Kleiner DE, Gaffey MJ, Sallie R , et al. Histopathologic changes associated with fialuridine hepatotoxicity. Mod Pathol 1997; 10 (3) 192-199
- 66 Berends MAM, Snoek J, de Jong EM , et al. Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent. Aliment Pharmacol Ther 2006; 24 (5) 805-811
- 67 Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006; 15 (4) 241-243
- 68 Senior JR. Regulatory perspectives. In: Kaplowitz N, DeLeve LD, , eds. Drug-Induced Liver Disease. New York, NY: Marcel Dekker; 2003: 739-754
- 69 Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42 (2) 481-489
- 70 Andrade RJ, Lucena MI, Fernández MC , et al; Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129 (2) 512-521
- 71 Food and Drug Administration. Guidance for clinical trial sponsors on the establishment and operation of clinical trial data monitoring committees. Available at: http://www.fda.gov/downloads/Regulatoryinformation/Guidances/ucm127073.pdf . Accessed January 7, 2014
- 72 Slutsky AS, Lavery JV. Data safety and monitoring boards. N Engl J Med 2004; 350 (11) 1143-1147
- 73 Guo T, Gelperin K, Senior J. A tool to help you decide (detect potentially serious liver injury). . Available at: http://www.fda.gov/downloads/Drugs/ScienceResearch/ResearchAreas/ucm076777.pdf . Accessed December 17, 2009
- 74 Watkins PB, Desai M, Berkowitz SD , et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf 2011; 34 (3) 243-252
- 75 Chitturi S, Farrell GC. Drug induced liver disease. In: Schiff ER, et al, eds. Schiff's diseases of the liver. 11th ed. Hoboken, NJ: Wiley-Blackwell; 2012: 703-782
- 76 Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis 2007; 11 (3) 477-505 , v
- 77 Fontana RJ, Watkins PB, Bonkovsky HL , et al; DILIN Study Group. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009; 32 (1) 55-68
- 78 Starkey Lewis PJ, Dear J, Platt V , et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 2011; 54 (5) 1767-1776
- 79 Locke JE, Sun Z, Warren DS , et al. Generation of humanized animal livers using embryoid body-derived stem cell transplant. Ann Surg 2008; 248 (3) 487-493